198 related articles for article (PubMed ID: 38508140)
21. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
22. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
[TBL] [Abstract][Full Text] [Related]
23. The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.
Gambi G; Di Simone E; Basso V; Ricci L; Wang R; Verma A; Elemento O; Ponzoni M; Inghirami G; Icardi L; Mondino A
Cancer Res; 2019 Jun; 79(12):3076-3087. PubMed ID: 30692217
[TBL] [Abstract][Full Text] [Related]
24. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
[TBL] [Abstract][Full Text] [Related]
25. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
[TBL] [Abstract][Full Text] [Related]
26. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
27. PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.
Garces de Los Fayos Alonso I; Zujo L; Wiest I; Kodajova P; Timelthaler G; Edtmayer S; Zrimšek M; Kollmann S; Giordano C; Kothmayer M; Neubauer HA; Dey S; Schlederer M; Schmalzbauer BS; Limberger T; Probst C; Pusch O; Högler S; Tangermann S; Merkel O; Schiefer AI; Kornauth C; Prutsch N; Zimmerman M; Abraham B; Anagnostopoulos J; Quintanilla-Martinez L; Mathas S; Wolf P; Stoiber D; Staber PB; Egger G; Klapper W; Woessmann W; Look TA; Gunning P; Turner SD; Moriggl R; Lagger S; Kenner L
Mol Cancer; 2022 Aug; 21(1):172. PubMed ID: 36045346
[TBL] [Abstract][Full Text] [Related]
28. The role of AP-1 and epigenetics in ALCL.
Schiefer AI; Vesely P; Hassler MR; Egger G; Kenner L
Front Biosci (Schol Ed); 2015 Jun; 7(2):226-35. PubMed ID: 25961698
[TBL] [Abstract][Full Text] [Related]
29. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
[TBL] [Abstract][Full Text] [Related]
30. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C; Nicolae A; Laurent C; Le Bras F; Haioun C; Fataccioli V; Amara N; Adélaïde J; Guille A; Schiano JM; Tesson B; Traverse-Glehen A; Chenard MP; Mescam L; Moreau A; Chassagne-Clement C; Somja J; Escudié F; André M; Martin N; Lacroix L; Lemonnier F; Hamy AS; Reyal F; Bannier M; Oberic L; Prade N; Frénois FX; Beldi-Ferchiou A; Delfau-Larue MH; Bouabdallah R; Birnbaum D; Brousset P; Xerri L; Gaulard P
Blood; 2020 Jan; 135(5):360-370. PubMed ID: 31774495
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.
Uchihara Y; Komori R; Tago K; Tamura H; Funakoshi-Tago M
Biochem Pharmacol; 2019 Dec; 170():113666. PubMed ID: 31654627
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.
Chen Z; Chai F; Xi Y; Zhang H; Xu Y; Zhang Z; Li S; Tian X
J Cancer Res Clin Oncol; 2022 Jan; 148(1):267-278. PubMed ID: 34131801
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
34. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
[TBL] [Abstract][Full Text] [Related]
35. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
36. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
37. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
38. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
40. Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.
Kalinova M; Mrhalova M; Kabickova E; Svaton M; Skotnicova A; Prouzova Z; Krenova Z; Kolenova A; Divoka M; Fronkova E; Kodet R
Mod Pathol; 2024 Mar; 37(3):100428. PubMed ID: 38266918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
